Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

UK Government published its Life Sciences Vision

In July 2021, the UK Government released its Life Sciences Vision, which sets out a 10-year strategy for the Life Sciences sector. Collaboratively with the UK's best academics, the National Health Service (NHS), and regulators, the Sector will accelerate the development of new drugs, diagnostics, MedTech, and digital tools to bring life-changing innovations to patients more quickly.

The Vision is focused on four themes:

  • Building on the new ways of working from COVID-19 to tackle future disease missions;
  • Building on the UK's science and clinical research infrastructure and harnessing the UK's unique genomic and health data;
  • Supporting the NHS to test, purchase and spread innovative technologies more effectively so that cutting-edge science and innovations can be embedded widely across the NHS as early as possible and rapidly adopted in the rest of the world;
  • Creating the right business environment in the UK in which companies can access the finance to grow, be regulated in an agile and efficient way, and manufacture and commercialize their products in the UK.

The Vision also identifies Healthcare Missions to help the NHS solving some of the most pressing healthcare challenges of our generation, such as cancer, obesity, dementia. These Missions will focus more on preventing, diagnosing, monitoring, and treating the disease early rather than providing late-stage interventions, using various innovations, including digital tools, diagnostics, and technologies. The Missions includes the following:

  • Improving translational capabilities in neurodegeneration and dementia;
  • Treatment and prevention of cardiovascular diseases and their major risk factors, including obesity;
  • Reducing mortality and morbidity from respiratory disease in the UK and globally;
  • Addressing the underlying biology of aging;

This Vision is a high-level document that specifies Government and the Life Sector's ambitions for the coming decade but does not set out the specific programs through which these will be delivered. The Government will set out its detailed delivery plan later, and the Sector will have the opportunity to decide where it wishes to co-invest.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).